ストックスクリーナーアプリを入手
2.40
4.00%
-0.10
アフターアワーズ：
2.41
0.01
+0.42%
前日終値:
$2.50
開ける：
$2.5
24時間の取引高:
246.27K
Relative Volume:
0.94
時価総額：
$23.43M
収益：
-
当期純損益:
$-31.88M
株価収益率:
-3.20
EPS:
-0.75
ネットキャッシュフロー:
$-25.20M
1週間 パフォーマンス:
+2.56%
1か月 パフォーマンス:
+34.83%
6か月 パフォーマンス:
+9.09%
1年 パフォーマンス:
-74.41%
1日の値動き範囲:
$2.15
$2.501
1週間の範囲:
$2.15
$2.60
52週間の値動き範囲:
$1.17
$12.53
In 8 Bio Inc Stock (INAB) Company Profile
INAB を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
2.40 | 24.40M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.68 | 122.84B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
801.01 | 85.37B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
399.40 | 55.82B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
795.57 | 50.67B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
170.27 | 37.54B | 447.02M | -1.18B | -906.14M | -6.1812 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-03-18 | 開始されました | Laidlaw | Buy |
| 2022-08-30 | 開始されました | H.C. Wainwright | Buy |
In 8 Bio Inc (INAB) 最新ニュース
Is Mustang Bio Inc. stock positioned for long term growthQuarterly Trade Review & Growth-Oriented Investment Plans - ulpravda.ru
Mercury Bio Launches MB-TIP™--Revolutionizing Immunotherapy with Intracellular Targeting - WV News
GRI Bio, Inc. Announces Positive Phase 2a Trial Data for GRI-0621 - TradingView — Track All Markets
Experimental drug shows signs of reversing lung scarring in IPF study - Stock Titan
Climb Bio Announces Pipeline Progress and Strategic Priorities for 2026 - TradingView — Track All Markets
How currency fluctuations impact Palisade Bio Inc. stockEx-Dividend Date Alerts & Low Entry Cost Investment - ulpravda.ru
FibroGen (NASDAQ: FGEN) rebrands as Kyntra Bio with new ticker KYNB - Stock Titan
Instil Bio Terminates License and Collaboration Agreement With ImmuneOnco Biopharmaceuticals - TradingView — Track All Markets
KALA BIO Signs Multiple Material Agreements - TradingView — Track All Markets
How a $2 million payment wiped out $10.6 million in company debt - Stock Titan
Provention Bio Appoints Miguel Sanjuan, Ph.D. as Senior Vice President of Research and Early Development - Quantisnow
Alumis Inc. Issues Notice of Material Breach to Climb Bio - TradingView — Track All Markets
Nuvation Bio stock today: NUVB slides nearly 7% as early gains fade - ts2.tech
The economy: Top biopharma trends of 2025 - BioWorld MedTech
Layoff Tracker: Nido Will Close Following Lead Candidate’s Disappointing Phase II Results - BioSpace
Intelligent Bio Solutions Inc Announces New Manufacturing Partnership - TradingView — Track All Markets
Climb Bio, Inc. Files Legal Complaint Over Asset Purchase Agreement - TradingView — Track All Markets
New gut-targeted drug gains key patent in Japan for severe bowel disease - Stock Titan
10 Stocks Lighting Up Market Ahead of Christmas - Insider Monkey
Ginkgo Bioworks (NYSE: DNA) realigns leadership as Shetty refocuses on lab - Stock Titan
Why Did Indaptus Therapeutics Surge 64% In After-Hours Trading? - Benzinga
Palisade Bio: Gut Prodrug For IBD With Catalysts - Seeking Alpha
What technical signals suggest for GRI Bio Inc. stockEarnings Growth Report & Safe Entry Point Identification - Улправда
Why Cabaletta Bio Inc. stock remains on watchlistsJuly 2025 Institutional & Weekly High Conviction Trade Ideas - Улправда
INmune Bio Signs Sales Agreement With A.G.P./Alliance Global Partners - TradingView — Track All Markets
BioMarin to Acquire Amicus Therapeutics for $4.8 Billion, Expanding Position as a Leader in Rare Diseases, Accelerating Revenue Growth and Strengthening Financial Outlook - BioMarin Pharmaceutical
Why GRI Bio Inc. stock remains on buy listsShare Buyback & Stepwise Trade Signal Implementation - Улправда
How sustainable is TELA Bio Inc. stock dividend payout2025 Pullback Review & Low Risk High Win Rate Picks - Улправда
Korro Bio (KRRO) boosts Jeffrey Cerio salary, severance and RSU grant - Stock Titan
Can Third Harmonic Bio Inc. stock withstand economic slowdownTrade Risk Assessment & Reliable Entry Point Alerts - Улправда
Pre Market Movers: ALGS, PDSB, PCSA Swing Big - RTTNews
Kala Bio (NASDAQ: KALA) details dismissal of Deloitte as auditor - Stock Titan
KALA BIO (Nasdaq: KALA) details Lazar financing shift and 2026 meeting - Stock Titan
BioCardia (NASDAQ: BCDA) moves to PMDA consultation on heart failure therapy - Stock Titan
Owner RA Capital Management LP Buys 314,561 ($754.7K) Of Climb Bio Inc [CLYM] - TradingView — Track All Markets
[8-K] ImmunityBio, Inc. Reports Material Event | IBRX SEC FilingForm 8-K - Stock Titan
Climb Bio (CLYM) director reports 20.44M-share exchange into pre-funded warrant - Stock Titan
GRI Bio (Nasdaq: GRI) details closing of offering, equity over $2.5M post-transaction - Stock Titan
GRI Bio Announces Closing of $8.0 Million Public Offering - GlobeNewswire
GRI Bio (NASDAQ: GRI) details $6.7M equity deal and runway into Q4 2026 - Stock Titan
GRI Bio (NASDAQ: GRI) prices $8,000,000 offering of 10,666,667 shares at $0.75 - Stock Titan
GRI Bio prices $8 million public offering at $0.75 per share - Investing.com India
Inmune Bio Ends Sales Agreement with RBC and BTIG - TipRanks
GRI Bio, Inc. Announces Positive Phase 2a Trial Results for GRI-0621 - TradingView
GRI Bio (NASDAQ: GRI) unveils Phase 2a IPF results showing favorable safety and collagen biomarker shifts - Stock Titan
ANVS SEC FilingsAnnovis Bio Inc 10-K, 10-Q, 8-K Forms - Stock Titan
GRI Bio (NASDAQ: GRI) updates Form S-1 with extensive warrant and contract exhibits - Stock Titan
Chmn Hoffman Buys 45,000 ($193.8K) Of Annovis Bio Inc [ANVS] - TradingView — Track All Markets
GRI Bio Reports Positive Phase 2a Trial Results for IPF Treatment - TradingView
GRI Bio (NASDAQ: GRI) reports Phase 2a IPF topline results for GRI-0621 - Stock Titan
GRI Bio (Nasdaq: GRI) reports positive IPF Phase 2a results and warrant offering - Stock Titan
In 8 Bio Inc (INAB) 財務データ
収益
当期純利益
現金流量
EPS
0.80%
4.63%
大文字化:
|
ボリューム (24 時間):